Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01273090 · ClinicalTrials.gov registry record · Phase 1
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01273090 is a Phase 1 study that has completed, run by Children's Oncology Group. The registered enrollment target is 34 participants.
The verdict
NCT01273090, a Phase 1 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in treating young patients with refractory or recurrent solid tumors or lymphoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG imetelstat sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01273090
The ClinicalTrials.gov registry entry for NCT01273090 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01273090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01273090 about?
NCT01273090 is a clinical study titled "Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma". RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in treating young patients with refractory or recurrent solid tumors or lympho...
What is the current status of trial NCT01273090?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2011-05. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01273090?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), imetelstat sodium (DRUG).
Who is sponsoring clinical trial NCT01273090?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.